FILANA THERAPEUTICS, INC. (FLNA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '10: 16.8M Q1 '11: 16.8M Q2 '11: 16.9M Q3 '11: 16.7M Q4 '11: 11.5M Q1 '12: 11.2M Q2 '12: 11.2M Q3 '12: 11.2M Q4 '12: 10.9M Q1 '13: 9.9M Q2 '13: 9.1M Q3 '13: 8.3M Q4 '13: 41.1M Q4 '10 Q2 '11 Q4 '11 Q2 '12 Q4 '12 Q2 '13 Q4 '13

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '10: -13.7M Q1 '11: -12.8M Q2 '11: -13M Q3 '11: -12.4M Q4 '11: -3.5M Q1 '12: -3.2M Q2 '12: -2M Q3 '12: -2.6M Q4 '12: -3.9M Q1 '13: -4.2M Q2 '13: -4.3M Q3 '13: -3.4M Q4 '13: 31.4M Q1 '14: 28.3M Q2 '14: 25.4M Q3 '14: 22.6M Q4 '14: -12.4M Q1 '15: -11.6M Q2 '15: -11.7M Q3 '15: -11.8M Q4 '15: -14.2M Q1 '16: -17.4M Q2 '16: -17.1M Q3 '16: -16.9M Q4 '16: -15M Q1 '17: -11.9M Q2 '17: -13M Q3 '17: -12.1M Q4 '17: -11.9M Q1 '18: -11.4M Q2 '18: -9.6M Q3 '18: -8.3M Q4 '18: -6.7M Q1 '19: -5.9M Q2 '19: -4.6M Q3 '19: -4.1M Q4 '19: -5M Q1 '20: -4.7M Q2 '20: -4.7M Q3 '20: -5.4M Q4 '20: -6.4M Q1 '21: -8.8M Q2 '21: -12.7M Q3 '21: -21M Q4 '21: -32.9M Q1 '22: -47.2M Q2 '22: -61.9M Q3 '22: -73.5M Q4 '22: -80M Q1 '23: -88.7M Q2 '23: -97.6M Q3 '23: -104.1M Q4 '23: -106M Q1 '24: -99.4M Q2 '24: -132M Q3 '24: -134.7M Q4 '24: -141.4M Q1 '25: -146.1M Q2 '25: -130.1M Q3 '25: -111.3M Q4 '25: -95.4M Q1 '26: -82M Q1 '12 Q1 '14 Q1 '16 Q1 '18 Q1 '20 Q1 '22 Q1 '24 Q1 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '10: -12M Q1 '11: -11.2M Q2 '11: -11.6M Q3 '11: -11.4M Q4 '11: -2.6M Q1 '12: -2.4M Q2 '12: -1.3M Q3 '12: -2M Q4 '12: -3.4M Q1 '13: -3.9M Q2 '13: -4.1M Q3 '13: -3.3M Q4 '13: 31.5M Q1 '14: 28.5M Q2 '14: 25.6M Q3 '14: 22.8M Q4 '14: -12.4M Q1 '15: -11.5M Q2 '15: -11.6M Q3 '15: -11.8M Q4 '15: -14.1M Q1 '16: -17.4M Q2 '16: -17M Q3 '16: -16.8M Q4 '16: -14.8M Q1 '17: -11.8M Q2 '17: -12.9M Q3 '17: -12M Q4 '17: -11.9M Q1 '18: -11.3M Q2 '18: -9.6M Q3 '18: -8.3M Q4 '18: -6.6M Q1 '19: -5.8M Q2 '19: -4.4M Q3 '19: -3.8M Q4 '19: -4.6M Q1 '20: -4.4M Q2 '20: -4.5M Q3 '20: -5.2M Q4 '20: -6.3M Q1 '21: -8.7M Q2 '21: -12.7M Q3 '21: -20.8M Q4 '21: -32.4M Q1 '22: -46.4M Q2 '22: -60.6M Q3 '22: -71.3M Q4 '22: -76.2M Q1 '23: -83M Q2 '23: -90M Q3 '23: -95.4M Q4 '23: -97.2M Q1 '24: -47.9M Q2 '24: -15.4M Q3 '24: -17.7M Q4 '24: -24.3M Q1 '25: -72.8M Q2 '25: -123.2M Q3 '25: -106M Q4 '25: -91M Q1 '26: -77.9M Q1 '12 Q1 '14 Q1 '16 Q1 '18 Q1 '20 Q1 '22 Q1 '24 Q1 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '11: -260K Q1 '12: -5.6M Q2 '12: -6M Q3 '12: -6.1M Q4 '12: -7.2M Q1 '13: -7M Q2 '13: -6.8M Q3 '13: -7.3M Q4 '13: -6.9M Q1 '14: -7.8M Q2 '14: -8.6M Q3 '14: -8.4M Q4 '14: -9.5M Q1 '15: -8M Q2 '15: -7.3M Q3 '15: -8.1M Q4 '15: -9.1M Q1 '16: -11M Q2 '16: -12.4M Q3 '16: -12.8M Q4 '16: -12.2M Q1 '17: -10.5M Q2 '17: -10.5M Q3 '17: -9.8M Q4 '17: -8.2M Q1 '18: -8.4M Q2 '18: -6.4M Q3 '18: -5.6M Q4 '18: -4.8M Q1 '19: -3.7M Q2 '19: -3.2M Q3 '19: -2.5M Q4 '19: -2.5M Q1 '20: -3.1M Q2 '20: -3.4M Q3 '20: -4.8M Q4 '20: -5.4M Q1 '21: -6.5M Q2 '21: -10.8M Q3 '21: -23.4M Q4 '21: -30.2M Q1 '22: -51.4M Q2 '22: -57.4M Q3 '22: -64.2M Q4 '22: -77.5M Q1 '23: -67.2M Q2 '23: -76M Q3 '23: -81M Q4 '23: -82M Q1 '24: -87.9M Q2 '24: -86.2M Q3 '24: -78M Q4 '24: -116.9M Q1 '25: -109.1M Q2 '25: -95.8M Q3 '25: -83.8M Q4 '25: -32.3M Q1 '26: -29.8M Q1 '12 Q1 '14 Q1 '16 Q1 '18 Q1 '20 Q1 '22 Q1 '24 Q1 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '14: -9.6M Q1 '15: -8.2M Q2 '15: -7.5M Q3 '15: -8.3M Q4 '15: -9.2M Q4 '19: -2.5M Q2 '22: -81.4M Q3 '22: -67.3M Q4 '23: -82.4M Q1 '24: -88M Q2 '24: -86.3M Q3 '24: -78.1M Q4 '24: -117M Q1 '25: -109.2M Q2 '25: -95.9M Q3 '25: -83.9M Q4 '25: -32.8M Q1 '15 Q4 '15 Q3 '22 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '11: 43.1M Q1 '12: 44.8M Q1 '13: 44.9M Q1 '22: 40M Q2 '22: 40M Q3 '22: 40M Q1 '23: 41.7M Q2 '23: 41.8M Q3 '23: 42M Q1 '24: 44.1M Q2 '24: 46.2M Q3 '24: 48M Q1 '25: 48.3M Q2 '25: 48.3M Q3 '25: 48.3M Q1 '11 Q1 '13 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '10: -0.28 Q1 '11: -0.25 Q2 '11: -0.26 Q3 '11: -0.26 Q4 '11: -0.06 Q1 '12: -0.06 Q2 '12: -0.03 Q3 '12: -0.04 Q4 '12: -0.07 Q1 '13: -0.08 Q2 '13: -0.09 Q3 '13: -0.08 Q4 '13: 0.68 Q1 '14: 0.61 Q2 '14: 0.55 Q3 '14: 0.49 Q4 '14: -0.28 Q1 '15: -0.26 Q2 '15: -0.26 Q3 '15: -0.26 Q4 '15: -0.31 Q1 '16: -0.38 Q2 '16: -0.77 Q3 '16: -1.23 Q4 '16: -1.19 Q1 '17: -1.48 Q2 '17: -1.66 Q3 '17: -1.52 Q4 '17: -1.83 Q1 '18: -1.74 Q2 '18: -1.46 Q3 '18: -1.17 Q4 '18: -0.61 Q1 '19: -0.36 Q2 '19: -0.06 Q3 '19: 0.01 Q4 '19: -0.27 Q1 '20: -0.24 Q2 '20: -0.23 Q3 '20: -0.25 Q4 '20: -0.25 Q1 '21: -0.29 Q2 '21: -0.37 Q3 '21: -0.55 Q4 '21: -0.82 Q1 '22: -1.17 Q2 '22: -1.52 Q3 '22: -1.79 Q4 '22: -1.90 Q1 '23: -2.04 Q2 '23: -2.19 Q3 '23: -2.29 Q4 '23: -2.32 Q1 '24: -2.17 Q2 '24: -1.41 Q3 '24: -1.38 Q4 '24: -1.46 Q1 '25: -1.51 Q2 '25: -2.56 Q3 '25: -2.20 Q4 '25: -1.88 Q1 '26: -1.61 Q1 '12 Q1 '14 Q1 '16 Q1 '18 Q1 '20 Q1 '22 Q1 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.